Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 2

Амброксол в программе лечения хронических бронхолегочных заболеваний
И.Л. Клячкина, А.И. Синопальников

References
1. Brooks SM. Perspective on the human cough reflex. Cough (London, England) 2011 Nov;7:10.
2. Morice AH. Epidemiology of cough. Pulmonary Pharmacology and Therapeutics 2002;15(3):253-9.
3. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2007 Aug;176(4):356-61.
4. Button B, Boucher RC; University of North Carolina Virtual Lung Group. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respiratory Physiology and Neurobiology 2008 Nov;163(1-3):189-201.
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. Updated 2014. Available from: http://www.goldcopd.org Accessed 2018 Sep 25.
6. Filleu GF, Beckwitt HJ, Reeves JT Mitchell RS. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. American Journal of Medicine 1968 Jan;44(1):26-38.
7. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. European Respiratory Journal 1995 Aug;8(8):1333-8.
8. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-Campos JL, Soriano JB, Ancochea J; Spanish Society of Pulmonology and Thoracic Surgery. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Archivos de Bronconeumología 2012 Jul;48(7):247-57.
9. Russian Respiratory Society. Chronic obstructive pulmonary disease: clinical guidelines. ICD 10: J44 approval year: 2016 (revision every 3 years). Available from: http://spulmo.ru Accessed 2018 Sep 25 (In Russian).
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease (2018 report). Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf Accessed 2018 Sep 25.
11. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015 Jul;(7):CD001287.
12. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. European Respiratory Review 2010 Jun;19(116):127-33.
13. Wiessmann KJ, Niemeyer K. Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author’s translation). Arzneimittel-Forschung 1978;28(5a):918-21.
14. Girod S, Galabert C, Pierrot D, Boissonnade MM, Zahm JM, Baszkin A, Puchelle E. Role of phospholipid lining on respiratory mucus clearance by cough. Journal of Applied Physiology (1985) 1991 Dec;71(6):2262-6.
15. Morgenroth K, Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration 1985;47(3):225-31.
16. Klyachkina IL, Sinopalnikov AI. Mucoactive drugs. In: Rational pharmacotherapy of respiratory diseases: a guide for practitioners. Ghuchalin AG, editor. 2nd ed. Moscow: Littera;2013:103-17 (In Russian).
17. Kimya Y, Küçükkömürcü S, Ozan H, Uncu G. Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects. Clinical and Experimental Obstetrics and Gynecology 1995;22(3):204-11.
18. Chenot JF, Weber P, Friede T. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Family Practice 2014 Mar;15:15-45.
19. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology 2008 Aug;4(8):1119-29.
20. Uchide N, Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications. Molecules (Basel, Switzerland) 2011 Feb;16(3):2032-52.
21. Kido H, Okumura Y, Yamada H, Le TQ, Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Current Pharmaceutical Design 2007;13(4):405-14.
22. Wang Y, Griffiths WJ, Curstedt T, Johansson J. Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a C-terminal 18-residue fragment thereof. FEBS Letters 1999 Oct;460(2):257-62.
23. Yang B, Yao DF, Ohuchi M, Ide M, Yano M, Okumura Y, Kido H. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. European Respiratory Journal 2002 May;19(5):952-8.
24. Aihara M, Dobashi K, Akiyama M, Naruse I, Nakazawa T, Mori M. Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages. Respiration 2000;67(6):662-71.
25. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. European Journal of Medical Research 2008 Dec;13(12):557-62.
26. Wiemeyer JC. Influence of ambroxol on the bronchopulmonary level of antibiotics. Arzneimittel-Forschung 1981;31(6):974-6.
27. Matsumae A, Toyoda S. Blood and lung levels of antibiotics after administration of a secretolytic substance NA 872 (ambroxol hydrochloride). Chemotherapy 1993;31:202-6.
28. Principi N, Zavattini G, Daniotti S. Possibility of interaction among antibiotics and mucolytics in children. International Journal Clinical Pharmacological Research 1986;6(5):369-72.
29. Perez-Neria J, Garcia Rubi E. Ambroxol–amoxiciline fixed combination vs. amoxiciline in acute infectious respiratory conditions – comparative study of antibiotic levels in bronchial mucus and blood. Compend Invest Clin Lat Am 1992;12(1):5-10.
30. Bonnetty P. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections. Investigación Médica Internacional 1993;20(2):99-103.
31. Spátola J, Poderoso JJ, Wiemeyer JC, Fernández M, Guerreiro RB, Corazza C. Influence of ambroxol on lung tissue penetration of amoxicillin. Arzneimittel-Forschung1987 Aug; 37(8):965-6.
32. Fraschini F, Scaglione F, Scarpazza G, Marchi F, Calzavara M. Effects of a mucolytic agent on the bioavailability of antibiotics in patients with chronic respiratory disease. Current Therapeutic Research 1988;43(4):734-42.
33. Zykov KA, Agapova OYu, Sokolov EI. New possibilities of Ambroxol application in pulmonology: impact on biofilms. Respiratory System Diseases. Consilium Medicum Supplement 2014;1:27-32 (In Russian).
34. Eldika N, Sethi S. Role of nontypeable Haemophilus influenzae in exacerbations and progression of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 2006 Mar;12(2):118-24.
35. Avdeev SN. Role of mucoactive drugs in chronic obstructive pulmonary disease treatment. Russian Pulmonology 2011;4:118-24 (In Russian).
36. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005 Apr-May;365(9470):1552-60.
37. Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, Shi Y, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo ZY, Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, Zhong NS. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008 Jun;371(9629):2013-8.
38. Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, Carnimeo N, Chianese R, Catena E, Marcatili S, Del Donno M, Grassi C, Pozzi E, Grassi V, Tantucci C, Lucchesi M, Schimid G, Marchioni C, Penitenti S, Mistretta A, Crimi N,·Casali L, Cabiddu R, Donner C, Patessio A, Massei V, Sanguinetti CM, Orlandi O, Bruna S, Serra C, Giacopelli A. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987;51(Suppl 1):42-51.
39. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulmonary Pharmacology and Therapeutics 2004;17(1):27-34.
40 Jullian S, Jaskiewicz L, Pfannkuche HJ, Parker J, Lalande-Luesink I, Lewis DJ, Close P. Aggregate analysis of regulatory authority assessors’ comments to improve the quality of periodic safety update reports. Pharmacoepidemiology and Drug Safety 2015 Sep;24(9):971-9.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]